On March 23, 2026, Apogee Therapeutics, Inc. reported positive maintenance data from the Phase 2 APEX trial of their drug, zumilokibart, showing durable efficacy in treating moderate-to-severe atopic dermatitis, with key findings indicating 88% overall response for 3-month dosing. The company plans to begin Phase 3 trials in late 2026, targeting a $50 billion market.